tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Chordia Therapeutics Announces Change in Major Shareholder

Story Highlights
  • Chordia Therapeutics operates in the pharmaceutical industry, focusing on innovative therapies.
  • A major shareholder reduced its stake, but no impact on management is expected.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Chordia Therapeutics Announces Change in Major Shareholder

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Chordia Therapeutics Inc. ( (JP:190A) ) is now available.

Chordia Therapeutics Inc. announced a change in its major shareholder, as Innovation Kyoto 2016 Investment Limited Liability Partnership reduced its voting rights from 10.14% to 9.99% due to the sale of common stock. This change is not expected to impact the company’s management or business performance.

More about Chordia Therapeutics Inc.

Chordia Therapeutics Inc. is a company operating in the pharmaceutical industry, focusing on the development of innovative therapies. The company is based in Fujisawa City, Kanagawa Prefecture, Japan, and is led by Chief Executive Officer Hiroshi Miyake.

Average Trading Volume: 874,392

Technical Sentiment Signal: Strong Sell

See more insights into 190A stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1